CareAcross

To hear about similar clinical trials, please enter your email below

I agree to receive (at most) monthly updates on similar research. I retain all GDPR rights. CareAcross will never share my email address.

Trial Title: Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

NCT ID: NCT05554367

Condition: Exocrine Pancreas Carcinoma
Malignant Solid Neoplasm
Ovarian Low Grade Serous Adenocarcinoma
Stage IV Ovarian Cancer AJCC v8
Stage IV Pancreatic Cancer AJCC v8

Conditions: Official terms:
Pancreatic Neoplasms
Cystadenocarcinoma, Serous
Palbociclib

Study type: Interventional

Study phase: Phase 2

Overall status: Recruiting

Study design:

Allocation: Randomized

Intervention model: Parallel Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: Binimetinib
Description: Given PO
Arm group label: Combination Cohorts 1, 2, 3, 4 (palbociclib, binimetinib)
Arm group label: Monotherapy Cohort 1 (binimetinib)

Other name: ARRY 162

Other name: ARRY 438162

Other name: ARRY-162

Other name: ARRY-438162

Other name: ARRY162

Other name: ARRY438162

Other name: MEK 162

Other name: MEK-162

Other name: MEK162

Other name: Mektovi

Intervention type: Procedure
Intervention name: Biopsy
Description: Undergo biopsy
Arm group label: Combination Cohorts 1, 2, 3, 4 (palbociclib, binimetinib)
Arm group label: Monotherapy Cohort 1 (binimetinib)

Other name: BIOPSY_TYPE

Other name: Bx

Intervention type: Procedure
Intervention name: Biospecimen Collection
Description: Undergo collection of blood samples
Arm group label: Combination Cohorts 1, 2, 3, 4 (palbociclib, binimetinib)
Arm group label: Monotherapy Cohort 1 (binimetinib)

Other name: Biological Sample Collection

Other name: Biospecimen Collected

Other name: Specimen Collection

Intervention type: Procedure
Intervention name: Bone Scan
Description: Undergo bone scan
Arm group label: Combination Cohorts 1, 2, 3, 4 (palbociclib, binimetinib)
Arm group label: Monotherapy Cohort 1 (binimetinib)

Other name: Bone Scintigraphy

Intervention type: Procedure
Intervention name: Computed Tomography
Description: Undergo CT
Arm group label: Combination Cohorts 1, 2, 3, 4 (palbociclib, binimetinib)
Arm group label: Monotherapy Cohort 1 (binimetinib)

Other name: CAT

Other name: CAT Scan

Other name: Computed Axial Tomography

Other name: Computerized Axial Tomography

Other name: Computerized axial tomography (procedure)

Other name: Computerized Tomography

Other name: Computerized Tomography (CT) scan

Other name: CT

Other name: CT Scan

Other name: tomography

Intervention type: Procedure
Intervention name: Magnetic Resonance Imaging
Description: Undergo MRI
Arm group label: Combination Cohorts 1, 2, 3, 4 (palbociclib, binimetinib)
Arm group label: Monotherapy Cohort 1 (binimetinib)

Other name: Magnetic Resonance

Other name: Magnetic Resonance Imaging (MRI)

Other name: Magnetic resonance imaging (procedure)

Other name: Magnetic Resonance Imaging Scan

Other name: Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance

Other name: MR

Other name: MR Imaging

Other name: MRI

Other name: MRI Scan

Other name: MRIs

Other name: NMR Imaging

Other name: NMRI

Other name: Nuclear Magnetic Resonance Imaging

Other name: sMRI

Other name: Structural MRI

Intervention type: Drug
Intervention name: Palbociclib
Description: Given PO
Arm group label: Combination Cohorts 1, 2, 3, 4 (palbociclib, binimetinib)

Other name: 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one

Other name: Ibrance

Other name: PD 0332991

Other name: PD 332991

Other name: PD 991

Other name: PD-0332991

Other name: PD0332991

Summary: This phase II ComboMATCH treatment trial evaluates the effectiveness of palbociclib and binimetinib in treating patients with RAS-mutated cancers. Palbociclib and binimetinib are both in a class of medications called kinase inhibitors. They work by blocking the action of abnormal proteins that signals cancer cells to multiply. This trial may help researchers understand if giving the combination of palbociclib and binimetinib can help improve the amount of time before the cancer grows in patients with patients with low grade serous ovarian cancer who have certain changes in the tumor DNA. This trial may also help researchers understand if giving the combination of palbociclib and binimetinib can help improve outcomes among patients with low grade serous ovarian cancer who have previously received a MEK inhibitor. For patients with other tumors, with the exception of lung cancer, colon cancer, melanoma and low grade serous ovarian cancers, this trial may help researchers understand if giving the combination of palbociclib and binimetinib can improve the clinical outcome of survival without progression in patients who have certain changes in their tumor's DNA.

Detailed description: PRIMARY OBJECTIVES: I. To determine whether palbociclib and binimetinib combination therapy improves progression free survival (PFS) compared to binimetinib alone in patients with MEK-inhibitor naive low-grade serous ovarian cancer (LGSOC) harboring MAP kinase activation (KRAS/NRAS/non BRAF V600E mutation). (Cohort 1) II. To determine whether palbociclib and binimetinib improves clinical activity in comparison to historical control, as measured by objective response rate (ORR), in women with LGSOC whose disease has previously progressed on a MEK inhibitor. (Cohort 2) III. To determine whether palbociclib and binimetinib combination therapy improves the objective response rate compared to historical control in patients with pancreatic cancer harboring any KRAS/NRAS/HRAS mutation or non-BRAF V600E aMOIs or rare RAF fusion. (Cohort 3) IV. To determine whether palbociclib and binimetinib combination therapy improves objective response rate compared to historical control in patients with tumors harboring any KRAS/NRAS/HRAS mutations or non-BRAF V600E aMOIs or rare RAF fusions (excluding LGSOC, non-small cell lung cancer [NSCLC], colorectal cancer, pancreatic cancer and melanoma). (Cohort 4) SECONDARY OBJECTIVES: I. To determine whether palbociclib and binimetinib combination therapy improves objective response rate (ORR), overall survival (OS), duration of response (DOR), and disease control rate (DCR) compared to binimetinib alone in patients with MEK inhibitor-naïve LGSOC. (Cohort 1) II. Conduct whole-exome sequencing to evaluate concordance with the designated laboratory result. (Cohort 1) III. To assess the clinical activity of palbociclib and binimetinib as measured by PFS, OS, DOR, and DCR in women with LGSOC whose disease has previously progressed on a MEK inhibitor. (Cohort 2) IV. Conduct whole-exome sequencing to evaluate concordance with the designated laboratory result. (Cohort 2) V. To assess the clinical activity of palbociclib and binimetinib as measured by PFS, OS, DOR, and DCR in patients with RAS mutated pancreatic cancer. (Cohort 3) VI. Conduct whole-exome sequencing to evaluate concordance with the designated laboratory result. (Cohort 3) VII. To assess the clinical activity of palbociclib and binimetinib as measured by PFS, OS, DOR, and DCR in patients with RAS mutated cancers, excluding LGSOC, NSCLC, colorectal cancer (CRC), pancreatic cancer and melanoma. (Cohort 4) VIII. Conduct whole-exome sequencing to evaluate concordance with the designated laboratory result. (Cohort 4) EXPLORATORY OBJECTIVES: I. Explore thymidine kinase 1 (TK1) activity in response to palbociclib. (Cohort 1) II. Assess the correlation between presence of KRAS mutation and activity of both monotherapy and the combination. (Cohort 1) III. Conduct ribonucleic acid (RNA)-sequencing (seq) to assess determinants of response and resistance. (Cohort 1) IV. Explore changes in plasma RAS allelic burden in KRAS-mutated tumors using circulating tumor deoxyribonucleic acid (ctDNA) and correlate changes with clinical activity. (Cohort 1) V. Explore TK1 activity in response to palbociclib.(Cohort 2) VI. Assess the correlation between presence of KRAS mutation and activity of the combination. (Cohort 2) VII. Conduct RNA-seq to assess determinants of response and resistance. (Cohort 2) VIII. Explore changes in plasma RAS allelic burden in KRAS-mutated tumors using ctDNA and correlate changes with clinical activity. (Cohort 2) IX. Explore TK1 activity in response to palbociclib. (Cohort 3) X. Evaluate changes in deoxyribonucleic acid (DNA), RNA and ctDNA to evaluate concordance with the designated laboratory result and to assess determinants of response, signatures of intrinsic resistance or response and the plasma RAS allelic burden in relation to treatment response, respectively. (Cohort 3) XI. Explore TK1 activity in response to palbociclib. (Cohort 4) XII. Evaluate changes in DNA, RNA and ctDNA to evaluate concordance with the designated laboratory result and to assess determinants of response, signatures of intrinsic resistance or response and the plasma RAS allelic burden in relation to treatment response, respectively. (Cohort 4) OUTLINE: Patients with KRAS, NRAS, non-BRAF V600E aMOIs or rare RAF fusions LGSOC, naïve to MEK or CDK4/6 inhibitor therapy are randomized to either combination cohort 1 or monotherapy cohort 1. Patients with LGSOC who have received prior MEK inhibitor therapy are assigned to combination cohort 2. Patients with KRAS/NRAS/HRAS/non-V600E a MOIs or rare RAF fusion pancreatic cancer are assigned to combination cohort 3. Patients with all other KRAS/NRAS/HRAS, non -BRAF V600E a MOIs or rare FAR fusion tumor types (excluding LGSOC, NSCLC, CRC, pancreatic, and melanoma) are assigned to combination cohort 4. COMBINATION COHORTS 1, 2, 3, 4: Patients receive palbociclib orally (PO), once per day (QD) on days 1-21 and binimetinib PO twice per day (BID) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity for up to 3 years. Patients may also undergo biopsy at screening and undergo magnetic resonance imaging (MRI), computed tomography (CT), bone scan, and collection of blood samples during screening, on study, and/or during follow up. MONOTHERAPY COHORT 1: Patients receive binimetinib PO BID daily, in the absence of disease progression or unacceptable toxicity, for up to 3 years. Patients who experience disease progression may elect to migrate to the combination cohort. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screening, on study, and/or during follow up. After completion of study treatment, patients are followed up every 3 months for up to 3 years following registration.

Criteria for eligibility:
Criteria:
Inclusion Criteria: - Patient must have enrolled onto EAY191 and must have been given a treatment assignment to ComboMATCH to EAY191-A3 based on the presence of an actionable mutation as defined in EAY191. - GENERAL ComboMATCH EAY191 REGISTRATION INCLUSION CRITERIA: - Patients must be enrolled on the EAY191 registration study and be assigned to this protocol by EAY191 - Patients must have KRAS/NRAS/HRAS or RAF mutations or rare RAF fusions as determined by the ComboMATCH screening assessment - Patients with low grade serous ovarian cancer who have progressed on a prior MEK inhibitor are not required to have a KRAS/NRAS/HRAS or BRAF alteration - Patients must not have a BRAF V600E alteration as determined by the ComboMATCH screening assessment - Patients with a tumor harboring KRAS G12C mutation will be eligible either after they have received a G12C inhibitor or can be enrolled if they do not meet eligibility for a G12C inhibitor. However, patients with tumors harboring KRAS G12C mutation will be prioritized for a G12C inhibitor-based substudy if eligible - Patients must have disease that can be safely biopsied and agree to a pre-treatment biopsy or have archival tissue available from within 12 months prior to registration - Please note the current actionable marker of interest (aMOI)/actionable alteration list for this treatment trial can be found on the Cancer Trials Support Unit (CTSU) website - EAY191-A3 IELIGIBILITY CRITERIA: - Histologically confirmed cancer for each cohort for which curable treatment modalities are not an option. Rare BRAF fusions and non-BRAF V600E aMOIs are acceptable. RB1 mutations or two copy RB1 deletions are excluded - Tumor tissue must be available: - Adequate archival tumor specimen (obtained within 12 months of EAY191 registration which has not had a Response Evaluation Criteria in Solid Tumors (RECIST) response, complete response (CR) or partial response (PR), to any intervening therapy after collection of the tissue) must be available with formalin-fixed paraffin-embedded tumor tissue (blocks or slides) OR - Consent to a new tumor tissue biopsy which is not a representative target lesion. This lesion must be amenable to a minimal risk image-guided or direct vision biopsy A new biopsy is preferred but is not required for enrollment in EAY191-A3 if sufficient archival tissue is available as described above - Measurable disease per RECIST 1.1. Of note, in the case when a baseline biopsy is done after scans are obtained, a lesion separate from one that is biopsied needs to be measurable per RECIST 1.1. All radiologic studies must be performed within 28 days prior to registration - COHORT 1: Low grade serous ovarian cancer with KRAS, NRAS non-BRAF V600E aMOIs or rare RAF fusions are acceptable - COHORT 1: No prior MEK inhibitor or CDK4/6 inhibitor therapy - COHORT 1: Any number of prior therapies permitted - COHORT 1: No major surgery within 4 weeks (excluding placement of vascular access), minor surgery within 2 weeks, or palliative radiotherapy within 2 weeks prior to registration - COHORT 1: No prior cancer-directed therapy within 28 days prior to registration. Patients may have received cancer-directed hormonal therapy up to 14 days prior to registration - COHORT 2: Low grade serous ovarian cancer - COHORT 2: Prior progression of disease on a MEK inhibitor (prior binimetinib permitted) - COHORT 2: If patient has previously received binimetinib, they cannot have required dose reduction or discontinuation of binimetinib due to adverse events - COHORT 2: No prior receipt of a CDK4/6 inhibitor - COHORT 2: No major surgery within 4 weeks (excluding placement of vascular access), minor surgery within 2 weeks, or palliative radiotherapy within 2 weeks prior to registration - COHORT 2: No prior cancer-directed therapy within 28 days prior to registration. Patients may have received cancer-directed hormonal therapy up to 14 days prior to registration - COHORT 3: Pancreatic cancer with KRAS/NRAS/HRAS, non-BRAF V600E aMOIs or rare RAF fusions are acceptable - COHORT 3: No prior MEK inhibitor (MEKi) and CDK4/6i therapy - COHORT 3: Progression after at least one line of prior therapy as long as there is no standard therapy available or acceptable to patients that is thought to be of benefit - COHORT 3: Any number of prior therapies are permitted - COHORT 3: No major surgery within 4 weeks (excluding placement of vascular access), minor surgery within 2 weeks, or palliative radiotherapy within 2 weeks prior to registration - COHORT 3: No prior cancer-directed therapy within 28 days prior to registration. Patients may have received cancer-directed hormonal therapy up to 14 days prior to registration - COHORT 4: KRAS/NRAS/HRAS non-BRAF V600E aMOIs or rare RAF fusions are acceptable - COHORT 4: No prior MEKi and CDK4/6i therapy and progression after at least one line of prior therapy, as long as there is no standard therapy available or acceptable to patients that is thought to be of benefit - COHORT 4: Any number of prior therapies are permitted - COHORT 4: No more than 6 patients with a given tumor type allowed in this cohort - COHORT 4: Any tumor type, except: LGSOC/NSCLC/CRC/pancreatic/melanoma - COHORT 4: No major surgery within 4 weeks (excluding placement of vascular access), minor surgery within 2 weeks, or palliative radiotherapy within 2 weeks prior to registration - COHORT 4: No prior cancer-directed therapy within 28 days prior to registration. Patients may have received cancer-directed hormonal therapy up to 14 days prior to registration - Not pregnant and not nursing, because this study involves investigational agents whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. Therefore, for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is required - Age >= 18 years - Eastern Cooperative Oncology Group (ECOG) performance status < 2 - Absolute neutrophil count (ANC) >= 1,500/mm^3 - Platelet count >= 100,000/mm^3 - Hemoglobin > 9 g/dL - Creatinine =< 1.5 x upper limit of normal (ULN) or calculated (calc.) creatinine clearance >= 30 mL/min as calculated by the Cockcroft-Gault formula - Total bilirubin =< 1.5 x upper limit of normal (ULN). Patients with Gilbert syndrome may enroll if total bilirubin (bili) < 3 mg/dL (51 micromole/L) - Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) - Creatine phosphokinase (CPK) =< 2.5 x ULN - Patients must be able to swallow oral formulations of the agents - No history of interstitial lung disease. No history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan - Patients should not have history of bowel perforation or intestinal fistulas in the last 6 months - No patients with the inability to swallow oral medications or impaired gastrointestinal absorption due to gastrectomy or active inflammatory bowel disease - No active skin disorder that has required systemic therapy within the past 1 year - No history of rhabdomyolysis - No concurrent ocular disorders including: - Subjects with history of glaucoma, history of retinal vein occlusion (RVO), predisposing factors for RVO, including uncontrolled hypertension, uncontrolled diabetes - Subject with history of retinal pathology or evidence of visible retinal pathology that is considered a risk factor for RVO, intraocular pressure > 21 mm Hg as measured by tonometry, or other significant ocular pathology, such as anatomical abnormalities that increase the risk for RVO - Subjects with a history of corneal erosion (instability of corneal epithelium), corneal degeneration, active or recurrent keratitis, and other forms of serious ocular surface inflammatory conditions - No patients with a history of hypersensitivity to any of the study drug(s) - No prior allogeneic stem cell or solid organ transplantation - Central nervous system (CNS) metastases must have been treated with local therapy (surgery, radiation, ablation) and patient off of systemic steroids, and brain metastases stable for at least 1 month - No residual Common Terminology Criteria for Adverse Events (CTCAE) >= grade 2 toxicity from any prior anticancer therapy, with the exception of grade 2 alopecia - Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial - For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated - Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load - Patients whose left ventricular ejection fraction (LVEF) has been evaluated by echocardiography (ECHO)/multigated acquisition scan (MUGA) are excluded if the most recent exam shows an LVEF < 50% - Chronic concomitant treatment with strong inhibitors of CYP3A4 is not allowed on this study. Patients on strong CYP3A4 inhibitors must discontinue the drug for 14 days prior to registration on the study - Chronic concomitant treatment with strong CYP3A4 inducers is not allowed. Patients must discontinue the drug 14 days prior to the start of study treatment - No exposure to P-glycoprotein (P-gp) inhibitors or inducers within 14 days prior to the first dose and during the course of therapy - Patients treated with Cohort 1 control treatment binimetinib who experience disease progression may elect to migrate to cohort 2 and receive combination treatment with palbociclib and binimetinib. Patients who choose to do so must meet laboratory values and performance status requirements as above and must be begin treatment within 21 days. For patients who migrate from cohort 1 to cohort 2, the 28-day window restricting prior anti-cancer directed therapies does not apply to prior binimetinib. A new biopsy will not be required for migration, but the optional biopsy at disease progression should be encouraged

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: University of Alabama at Birmingham Cancer Center

Address:
City: Birmingham
Zip: 35233
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 205-934-0220
Email: tmyrick@uab.edu

Investigator:
Last name: Rebecca C. Arend
Email: Principal Investigator

Facility:
Name: University of South Alabama Mitchell Cancer Institute

Address:
City: Mobile
Zip: 36688
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 251-445-9870
Email: pfrancisco@usouthal.edu

Investigator:
Last name: Ahmed Abdalla
Email: Principal Investigator

Facility:
Name: UCHealth University of Colorado Hospital

Address:
City: Aurora
Zip: 80045
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 720-848-0650

Investigator:
Last name: Robert W. Lentz
Email: Principal Investigator

Facility:
Name: Poudre Valley Hospital

Address:
City: Fort Collins
Zip: 80524
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 970-297-6150

Investigator:
Last name: Robert W. Lentz
Email: Principal Investigator

Facility:
Name: Cancer Care and Hematology-Fort Collins

Address:
City: Fort Collins
Zip: 80528
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 773-702-9171
Email: protocols@AllianceNCTN.org

Investigator:
Last name: Robert W. Lentz
Email: Principal Investigator

Facility:
Name: UCHealth Greeley Hospital

Address:
City: Greeley
Zip: 80631
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 773-702-9171
Email: protocols@AllianceNCTN.org

Investigator:
Last name: Robert W. Lentz
Email: Principal Investigator

Facility:
Name: Medical Center of the Rockies

Address:
City: Loveland
Zip: 80538
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 970-203-7083

Investigator:
Last name: Robert W. Lentz
Email: Principal Investigator

Facility:
Name: UM Sylvester Comprehensive Cancer Center at Aventura

Address:
City: Aventura
Zip: 33180
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 954-461-2180

Investigator:
Last name: Chukwuemeka (Emeka) V. Ikpeazu
Email: Principal Investigator

Facility:
Name: UM Sylvester Comprehensive Cancer Center at Coral Gables

Address:
City: Coral Gables
Zip: 33146
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 305-243-2647

Investigator:
Last name: Chukwuemeka (Emeka) V. Ikpeazu
Email: Principal Investigator

Facility:
Name: UM Sylvester Comprehensive Cancer Center at Deerfield Beach

Address:
City: Deerfield Beach
Zip: 33442
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 305-243-2647

Investigator:
Last name: Chukwuemeka (Emeka) V. Ikpeazu
Email: Principal Investigator

Facility:
Name: University of Florida Health Science Center - Gainesville

Address:
City: Gainesville
Zip: 32610
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 352-273-8010
Email: cancer-center@ufl.edu

Investigator:
Last name: Thomas J. George
Email: Principal Investigator

Facility:
Name: University of Miami Miller School of Medicine-Sylvester Cancer Center

Address:
City: Miami
Zip: 33136
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 305-243-2647

Investigator:
Last name: Chukwuemeka (Emeka) V. Ikpeazu
Email: Principal Investigator

Facility:
Name: UM Sylvester Comprehensive Cancer Center at Kendall

Address:
City: Miami
Zip: 33176
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 305-243-2647

Investigator:
Last name: Chukwuemeka (Emeka) V. Ikpeazu
Email: Principal Investigator

Facility:
Name: UM Sylvester Comprehensive Cancer Center at Plantation

Address:
City: Plantation
Zip: 33324
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 305-243-2647

Investigator:
Last name: Chukwuemeka (Emeka) V. Ikpeazu
Email: Principal Investigator

Facility:
Name: Saint Alphonsus Cancer Care Center-Boise

Address:
City: Boise
Zip: 83706
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 734-712-3671
Email: stephanie.couch@stjoeshealth.org

Investigator:
Last name: John M. Schallenkamp
Email: Principal Investigator

Facility:
Name: Saint Luke's Cancer Institute - Boise

Address:
City: Boise
Zip: 83712
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 208-381-2774
Email: eslinget@slhs.org

Investigator:
Last name: Alison K. Conlin
Email: Principal Investigator

Facility:
Name: Saint Alphonsus Cancer Care Center-Caldwell

Address:
City: Caldwell
Zip: 83605
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 734-712-3671
Email: stephanie.couch@stjoeshealth.org

Investigator:
Last name: John M. Schallenkamp
Email: Principal Investigator

Facility:
Name: Kootenai Health - Coeur d'Alene

Address:
City: Coeur d'Alene
Zip: 83814
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 406-969-6060
Email: mccinfo@mtcancer.org

Investigator:
Last name: John M. Schallenkamp
Email: Principal Investigator

Facility:
Name: Saint Luke's Cancer Institute - Fruitland

Address:
City: Fruitland
Zip: 83619
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 208-381-2774
Email: eslinget@slhs.org

Investigator:
Last name: Alison K. Conlin
Email: Principal Investigator

Facility:
Name: Saint Luke's Cancer Institute - Meridian

Address:
City: Meridian
Zip: 83642
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 208-381-2774
Email: eslinget@slhs.org

Investigator:
Last name: Alison K. Conlin
Email: Principal Investigator

Facility:
Name: Saint Alphonsus Cancer Care Center-Nampa

Address:
City: Nampa
Zip: 83687
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 406-969-6060
Email: mccinfo@mtcancer.org

Investigator:
Last name: John M. Schallenkamp
Email: Principal Investigator

Facility:
Name: Saint Luke's Cancer Institute - Nampa

Address:
City: Nampa
Zip: 83687
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 208-381-2774
Email: eslinget@slhs.org

Investigator:
Last name: Alison K. Conlin
Email: Principal Investigator

Facility:
Name: Kootenai Clinic Cancer Services - Post Falls

Address:
City: Post Falls
Zip: 83854
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 406-969-6060
Email: mccinfo@mtcancer.org

Investigator:
Last name: John M. Schallenkamp
Email: Principal Investigator

Facility:
Name: Kootenai Clinic Cancer Services - Sandpoint

Address:
City: Sandpoint
Zip: 83864
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 406-969-6060
Email: mccinfo@mtcancer.org

Investigator:
Last name: John M. Schallenkamp
Email: Principal Investigator

Facility:
Name: Advocate Good Shepherd Hospital

Address:
City: Barrington
Zip: 60010
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 847-842-4847

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: Illinois CancerCare-Bloomington

Address:
City: Bloomington
Zip: 61704
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 309-243-3605
Email: andersonj@illinoiscancercare.com

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Illinois CancerCare-Canton

Address:
City: Canton
Zip: 61520
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 309-243-3605
Email: andersonj@illinoiscancercare.com

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Illinois CancerCare-Carthage

Address:
City: Carthage
Zip: 62321
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 309-243-3605
Email: andersonj@illinoiscancercare.com

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Northwestern University

Address:
City: Chicago
Zip: 60611
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 312-695-1301
Email: cancer@northwestern.edu

Investigator:
Last name: Devalingam Mahalingam
Email: Principal Investigator

Facility:
Name: John H Stroger Jr Hospital of Cook County

Address:
City: Chicago
Zip: 60612
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 312-864-5204

Investigator:
Last name: Thomas E. Lad
Email: Principal Investigator

Facility:
Name: University of Chicago Comprehensive Cancer Center

Address:
City: Chicago
Zip: 60637
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 773-702-8222
Email: cancerclinicaltrials@bsd.uchicago.edu

Investigator:
Last name: Ardaman Shergill
Email: Principal Investigator

Facility:
Name: Advocate Illinois Masonic Medical Center

Address:
City: Chicago
Zip: 60657
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 773-296-5360

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: AMG Crystal Lake - Oncology

Address:
City: Crystal Lake
Zip: 60014
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 630-929-6129
Email: advocateresearch@advocate.com

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: Carle at The Riverfront

Address:
City: Danville
Zip: 61832
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-446-5532
Email: Research@Carle.com

Investigator:
Last name: Maria T. Grosse-Perdekamp
Email: Principal Investigator

Facility:
Name: Cancer Care Specialists of Illinois - Decatur

Address:
City: Decatur
Zip: 62526
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 217-876-4762
Email: morganthaler.jodi@mhsil.com

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Decatur Memorial Hospital

Address:
City: Decatur
Zip: 62526
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 217-876-4762
Email: morganthaler.jodi@mhsil.com

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Northwestern Medicine Cancer Center Kishwaukee

Address:
City: DeKalb
Zip: 60115
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 630-352-5360
Email: Donald.Smith3@nm.org

Investigator:
Last name: Devalingam Mahalingam
Email: Principal Investigator

Facility:
Name: Illinois CancerCare-Dixon

Address:
City: Dixon
Zip: 61021
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 815-285-7800

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Advocate Good Samaritan Hospital

Address:
City: Downers Grove
Zip: 60515
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 630-275-1270
Email: Barbara.barhamand@advocatehealth.com

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: Carle Physician Group-Effingham

Address:
City: Effingham
Zip: 62401
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-446-5532
Email: Research@carle.com

Investigator:
Last name: Maria T. Grosse-Perdekamp
Email: Principal Investigator

Facility:
Name: Crossroads Cancer Center

Address:
City: Effingham
Zip: 62401
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 217-876-4762
Email: morganthaler.jodi@mhsil.com

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Advocate Sherman Hospital

Address:
City: Elgin
Zip: 60123
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 847-429-2907

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: Illinois CancerCare-Eureka

Address:
City: Eureka
Zip: 61530
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 309-243-3605
Email: andersonj@illinoiscancercare.com

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Illinois CancerCare-Galesburg

Address:
City: Galesburg
Zip: 61401
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 309-243-3605
Email: andersonj@illinoiscancercare.com

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Northwestern Medicine Cancer Center Delnor

Address:
City: Geneva
Zip: 60134
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 630-352-5360
Email: Donald.Smith3@nm.org

Investigator:
Last name: Devalingam Mahalingam
Email: Principal Investigator

Facility:
Name: Northwestern Medicine Glenview Outpatient Center

Address:
City: Glenview
Zip: 60026
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 312-695-1102

Investigator:
Last name: Devalingam Mahalingam
Email: Principal Investigator

Facility:
Name: Northwestern Medicine Grayslake Outpatient Center

Address:
City: Grayslake
Zip: 60030
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 312-695-1102

Investigator:
Last name: Devalingam Mahalingam
Email: Principal Investigator

Facility:
Name: Advocate South Suburban Hospital

Address:
City: Hazel Crest
Zip: 60429
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 708-799-9995

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: Illinois CancerCare-Kewanee Clinic

Address:
City: Kewanee
Zip: 61443
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 309-243-3605
Email: andersonj@illinoiscancercare.com

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Northwestern Medicine Lake Forest Hospital

Address:
City: Lake Forest
Zip: 60045
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact
Email: cancertrials@northwestern.edu

Investigator:
Last name: Devalingam Mahalingam
Email: Principal Investigator

Facility:
Name: AMG Libertyville - Oncology

Address:
City: Libertyville
Zip: 60048
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 630-929-6129
Email: advocateresearch@advocatehealth.com

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: Condell Memorial Hospital

Address:
City: Libertyville
Zip: 60048
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 630-929-6129
Email: advocateresearch@advocatehealth.com

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: Illinois CancerCare-Macomb

Address:
City: Macomb
Zip: 61455
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 309-243-3605
Email: andersonj@illinoiscancercare.com

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Carle Physician Group-Mattoon/Charleston

Address:
City: Mattoon
Zip: 61938
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-446-5532
Email: Research@carle.com

Investigator:
Last name: Maria T. Grosse-Perdekamp
Email: Principal Investigator

Facility:
Name: UC Comprehensive Cancer Center at Silver Cross

Address:
City: New Lenox
Zip: 60451
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 773-702-8222
Email: cancerclinicaltrials@bsd.uchicago.edu

Investigator:
Last name: Ardaman Shergill
Email: Principal Investigator

Facility:
Name: Cancer Care Center of O'Fallon

Address:
City: O'Fallon
Zip: 62269
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 217-876-4762
Email: morganthaler.jodi@mhsil.com

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Advocate Christ Medical Center

Address:
City: Oak Lawn
Zip: 60453-2699
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-323-8622

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: Advocate Outpatient Center - Oak Lawn

Address:
City: Oak Lawn
Zip: 60453
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact
Email: ncorp@aah.org

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: Northwestern Medicine Orland Park

Address:
City: Orland Park
Zip: 60462
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact
Email: nctnprogram_rhlccc@northwestern.edu

Investigator:
Last name: Devalingam Mahalingam
Email: Principal Investigator

Facility:
Name: University of Chicago Medicine-Orland Park

Address:
City: Orland Park
Zip: 60462
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 773-702-8222
Email: cancerclinicaltrials@bsd.uchicago.edu

Investigator:
Last name: Ardaman Shergill
Email: Principal Investigator

Facility:
Name: Illinois CancerCare-Ottawa Clinic

Address:
City: Ottawa
Zip: 61350
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 309-243-3605
Email: andersonj@illinoiscancercare.com

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Advocate High Tech Medical Park

Address:
City: Palos Heights
Zip: 60463
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact
Email: ncorp@aah.org

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: Advocate Lutheran General Hospital

Address:
City: Park Ridge
Zip: 60068
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 847-384-3621

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: Illinois CancerCare-Pekin

Address:
City: Pekin
Zip: 61554
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 309-243-3605
Email: andersonj@illinoiscancercare.com

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Illinois CancerCare-Peoria

Address:
City: Peoria
Zip: 61615
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 309-243-3605
Email: andersonj@illinoiscancercare.com

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Illinois CancerCare-Peru

Address:
City: Peru
Zip: 61354
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 309-243-3605
Email: andersonj@illinoiscancercare.com

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Illinois CancerCare-Princeton

Address:
City: Princeton
Zip: 61356
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 309-243-3605
Email: andersonj@illinoiscancercare.com

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Southern Illinois University School of Medicine

Address:
City: Springfield
Zip: 62702
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 217-545-7929

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Springfield Clinic

Address:
City: Springfield
Zip: 62702
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-444-7541

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Springfield Memorial Hospital

Address:
City: Springfield
Zip: 62781
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 217-528-7541
Email: pallante.beth@mhsil.com

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Carle Cancer Center

Address:
City: Urbana
Zip: 61801
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-446-5532
Email: Research@carle.com

Investigator:
Last name: Maria T. Grosse-Perdekamp
Email: Principal Investigator

Facility:
Name: Northwestern Medicine Cancer Center Warrenville

Address:
City: Warrenville
Zip: 60555
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 630-352-5360
Email: Donald.Smith3@nm.org

Investigator:
Last name: Devalingam Mahalingam
Email: Principal Investigator

Facility:
Name: Illinois CancerCare - Washington

Address:
City: Washington
Zip: 61571
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 309-243-3605
Email: andersonj@illinoiscancercare.com

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Mission Cancer and Blood - Ankeny

Address:
City: Ankeny
Zip: 50023
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 515-282-2921

Investigator:
Last name: Richard L. Deming
Email: Principal Investigator

Facility:
Name: Mercy Hospital

Address:
City: Cedar Rapids
Zip: 52403
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 319-365-4673

Investigator:
Last name: Deborah W. Wilbur
Email: Principal Investigator

Facility:
Name: Oncology Associates at Mercy Medical Center

Address:
City: Cedar Rapids
Zip: 52403
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 319-363-2690

Investigator:
Last name: Deborah W. Wilbur
Email: Principal Investigator

Facility:
Name: Mission Cancer and Blood - Des Moines

Address:
City: Des Moines
Zip: 50309
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 515-241-3305

Investigator:
Last name: Seema Harichand-Herdt
Email: Principal Investigator

Facility:
Name: University of Kentucky/Markey Cancer Center

Address:
City: Lexington
Zip: 40536
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 859-257-3379

Investigator:
Last name: Susanne M. Arnold
Email: Principal Investigator

Facility:
Name: Harold Alfond Center for Cancer Care

Address:
City: Augusta
Zip: 04330
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 207-626-4855

Investigator:
Last name: Leslie S. Bradford
Email: Principal Investigator

Facility:
Name: Lafayette Family Cancer Center-EMMC

Address:
City: Brewer
Zip: 04412
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-987-3005

Investigator:
Last name: Sarah J. Sinclair
Email: Principal Investigator

Facility:
Name: Maine Medical Center- Scarborough Campus

Address:
City: Scarborough
Zip: 04074
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 207-396-8090
Email: wrighd@mmc.org

Investigator:
Last name: Leslie S. Bradford
Email: Principal Investigator

Facility:
Name: Maine Medical Partners - South Portland

Address:
City: South Portland
Zip: 04106
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 207-396-8670
Email: ClinicalResearch@mmc.org

Investigator:
Last name: Leslie S. Bradford
Email: Principal Investigator

Facility:
Name: University of Maryland/Greenebaum Cancer Center

Address:
City: Baltimore
Zip: 21201
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-888-8823

Investigator:
Last name: Ranee Mehra
Email: Principal Investigator

Facility:
Name: National Institutes of Health Clinical Center

Address:
City: Bethesda
Zip: 20892
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-411-1222

Investigator:
Last name: Jibran Ahmed
Email: Principal Investigator

Facility:
Name: UPMC Western Maryland

Address:
City: Cumberland
Zip: 21502
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 240-964-1400

Investigator:
Last name: Sarah E. Taylor
Email: Principal Investigator

Facility:
Name: Dana-Farber Cancer Institute

Address:
City: Boston
Zip: 02215
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 877-442-3324

Investigator:
Last name: Geoffrey I. Shapiro
Email: Principal Investigator

Facility:
Name: Trinity Health Saint Joseph Mercy Hospital Ann Arbor

Address:
City: Ann Arbor
Zip: 48106
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 734-712-7251
Email: MCRCwebsitecontactform@stjoeshealth.org

Investigator:
Last name: Tareq Al baghdadi
Email: Principal Investigator

Facility:
Name: Bronson Battle Creek

Address:
City: Battle Creek
Zip: 49017
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 616-391-1230
Email: crcwm-regulatory@crcwm.org

Investigator:
Last name: Kathleen J. Yost
Email: Principal Investigator

Facility:
Name: Trinity Health IHA Medical Group Hematology Oncology - Brighton

Address:
City: Brighton
Zip: 48114
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 734-712-7251
Email: MCRCwebsitecontactform@stjoeshealth.org

Investigator:
Last name: Tareq Al baghdadi
Email: Principal Investigator

Facility:
Name: Trinity Health Medical Center - Brighton

Address:
City: Brighton
Zip: 48114
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 734-712-7251
Email: MCRCwebsitecontactform@stjoeshealth.org

Investigator:
Last name: Tareq Al baghdadi
Email: Principal Investigator

Facility:
Name: Trinity Health IHA Medical Group Hematology Oncology - Canton

Address:
City: Canton
Zip: 48188
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 734-712-7251
Email: MCRCwebsitecontactform@stjoeshealth.org

Investigator:
Last name: Tareq Al baghdadi
Email: Principal Investigator

Facility:
Name: Trinity Health Medical Center - Canton

Address:
City: Canton
Zip: 48188
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 734-712-7251
Email: MCRCwebsitecontactform@stjoeshealth.org

Investigator:
Last name: Tareq Al baghdadi
Email: Principal Investigator

Facility:
Name: Chelsea Hospital

Address:
City: Chelsea
Zip: 48118
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 734-712-7251
Email: MCRCwebsitecontactform@stjoeshealth.org

Investigator:
Last name: Tareq Al baghdadi
Email: Principal Investigator

Facility:
Name: Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

Address:
City: Chelsea
Zip: 48118
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 734-712-7251
Email: MCRCwebsitecontactform@stjoeshealth.org

Investigator:
Last name: Tareq Al baghdadi
Email: Principal Investigator

Facility:
Name: Corewell Health Dearborn Hospital

Address:
City: Dearborn
Zip: 48124
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 248-551-7695

Investigator:
Last name: Dana Zakalik
Email: Principal Investigator

Facility:
Name: OSF Saint Francis Hospital and Medical Group

Address:
City: Escanaba
Zip: 49829
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 920-433-8889
Email: ewd_research_admin@hshs.org

Investigator:
Last name: Anthony J. Jaslowski
Email: Principal Investigator

Facility:
Name: Corewell Health Farmington Hills Hospital

Address:
City: Farmington Hills
Zip: 48336
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 248-551-7695

Investigator:
Last name: Dana Zakalik
Email: Principal Investigator

Facility:
Name: Genesee Cancer and Blood Disease Treatment Center

Address:
City: Flint
Zip: 48503
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 810-762-8038
Email: wstrong@ghci.org

Investigator:
Last name: Tareq Al baghdadi
Email: Principal Investigator

Facility:
Name: Genesee Hematology Oncology PC

Address:
City: Flint
Zip: 48503
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 810-762-8038
Email: wstrong@ghci.org

Investigator:
Last name: Tareq Al baghdadi
Email: Principal Investigator

Facility:
Name: Genesys Hurley Cancer Institute

Address:
City: Flint
Zip: 48503
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 810-762-8038
Email: wstrong@ghci.org

Investigator:
Last name: Tareq Al baghdadi
Email: Principal Investigator

Facility:
Name: Hurley Medical Center

Address:
City: Flint
Zip: 48503
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 810-762-8038
Email: wstrong@ghci.org

Investigator:
Last name: Tareq Al baghdadi
Email: Principal Investigator

Facility:
Name: Corewell Health Grand Rapids Hospitals - Butterworth Hospital

Address:
City: Grand Rapids
Zip: 49503
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 616-391-1230
Email: crcwm-regulatory@crcwm.org

Investigator:
Last name: Kathleen J. Yost
Email: Principal Investigator

Facility:
Name: Trinity Health Grand Rapids Hospital

Address:
City: Grand Rapids
Zip: 49503
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 616-391-1230
Email: crcwm-regulatory@crcwm.org

Investigator:
Last name: Kathleen J. Yost
Email: Principal Investigator

Facility:
Name: Bronson Methodist Hospital

Address:
City: Kalamazoo
Zip: 49007
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 616-391-1230
Email: crcwm-regulatory@crcwm.org

Investigator:
Last name: Kathleen J. Yost
Email: Principal Investigator

Facility:
Name: West Michigan Cancer Center

Address:
City: Kalamazoo
Zip: 49007
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 616-391-1230
Email: crcwm-regulatory@crcwm.org

Investigator:
Last name: Kathleen J. Yost
Email: Principal Investigator

Facility:
Name: Ascension Borgess Cancer Center

Address:
City: Kalamazoo
Zip: 49009
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 616-391-1230
Email: crcwm-regulatory@crcwm.org

Investigator:
Last name: Kathleen J. Yost
Email: Principal Investigator

Facility:
Name: University of Michigan Health - Sparrow Lansing

Address:
City: Lansing
Zip: 48912
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 517-364-3712
Email: harsha.trivedi@umhsparrow.org

Investigator:
Last name: Tareq Al baghdadi
Email: Principal Investigator

Facility:
Name: Trinity Health Saint Mary Mercy Livonia Hospital

Address:
City: Livonia
Zip: 48154
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 734-712-7251
Email: MCRCwebsitecontactform@stjoeshealth.org

Investigator:
Last name: Tareq Al baghdadi
Email: Principal Investigator

Facility:
Name: Trinity Health Muskegon Hospital

Address:
City: Muskegon
Zip: 49444
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 616-391-1230
Email: crcwm-regulatory@crcwm.org

Investigator:
Last name: Kathleen J. Yost
Email: Principal Investigator

Facility:
Name: Corewell Health Lakeland Hospitals - Niles Hospital

Address:
City: Niles
Zip: 49120
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 616-391-1230

Investigator:
Last name: Kathleen J. Yost
Email: Principal Investigator

Facility:
Name: Cancer and Hematology Centers of Western Michigan - Norton Shores

Address:
City: Norton Shores
Zip: 49444
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 616-391-1230
Email: connie.szczepanek@crcwm.org

Investigator:
Last name: Kathleen J. Yost
Email: Principal Investigator

Facility:
Name: Michigan Healthcare Professionals Pontiac

Address:
City: Pontiac
Zip: 48341
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 248-858-6215
Email: Emily.Crofts@trinity-health.org

Investigator:
Last name: Tareq Al baghdadi
Email: Principal Investigator

Facility:
Name: Trinity Health Saint Joseph Mercy Oakland Hospital

Address:
City: Pontiac
Zip: 48341
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 734-712-7251
Email: MCRCwebsitecontactform@stjoeshealth.org

Investigator:
Last name: Tareq Al baghdadi
Email: Principal Investigator

Facility:
Name: Corewell Health Reed City Hospital

Address:
City: Reed City
Zip: 49677
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 616-391-1230
Email: crcwm-regulatory@crcwm.org

Investigator:
Last name: Kathleen J. Yost
Email: Principal Investigator

Facility:
Name: Corewell Health William Beaumont University Hospital

Address:
City: Royal Oak
Zip: 48073
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 248-551-7695

Investigator:
Last name: Dana Zakalik
Email: Principal Investigator

Facility:
Name: Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center

Address:
City: Saint Joseph
Zip: 49085
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 616-391-1230
Email: crcwm-regulatory@crcwm.org

Investigator:
Last name: Kathleen J. Yost
Email: Principal Investigator

Facility:
Name: Corewell Health Lakeland Hospitals - Saint Joseph Hospital

Address:
City: Saint Joseph
Zip: 49085
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 616-391-1230
Email: crcwm-regulatory@crcwm.org

Investigator:
Last name: Kathleen J. Yost
Email: Principal Investigator

Facility:
Name: Munson Medical Center

Address:
City: Traverse City
Zip: 49684
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 616-391-1230
Email: crcwm-regulatory@crcwm.org

Investigator:
Last name: Kathleen J. Yost
Email: Principal Investigator

Facility:
Name: Corewell Health Beaumont Troy Hospital

Address:
City: Troy
Zip: 48085
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 248-551-7695

Investigator:
Last name: Dana Zakalik
Email: Principal Investigator

Facility:
Name: University of Michigan Health - West

Address:
City: Wyoming
Zip: 49519
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 616-391-1230
Email: crcwm-regulatory@crcwm.org

Investigator:
Last name: Kathleen J. Yost
Email: Principal Investigator

Facility:
Name: Huron Gastroenterology PC

Address:
City: Ypsilanti
Zip: 48106
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 734-712-7251
Email: MCRCwebsitecontactform@stjoeshealth.org

Investigator:
Last name: Tareq Al baghdadi
Email: Principal Investigator

Facility:
Name: Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus

Address:
City: Ypsilanti
Zip: 48197
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 734-712-7251
Email: MCRCwebsitecontactform@stjoeshealth.org

Investigator:
Last name: Tareq Al baghdadi
Email: Principal Investigator

Facility:
Name: Sanford Joe Lueken Cancer Center

Address:
City: Bemidji
Zip: 56601
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 218-333-5000
Email: OncologyClinicalTrialsFargo@sanfordhealth.org

Investigator:
Last name: Daniel Almquist
Email: Principal Investigator

Facility:
Name: Essentia Health - Deer River Clinic

Address:
City: Deer River
Zip: 56636
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 218-786-3308
Email: CancerTrials@EssentiaHealth.org

Investigator:
Last name: Bret E. Friday
Email: Principal Investigator

Facility:
Name: Essentia Health Cancer Center

Address:
City: Duluth
Zip: 55805
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 218-786-3308
Email: CancerTrials@EssentiaHealth.org

Investigator:
Last name: Bret E. Friday
Email: Principal Investigator

Facility:
Name: Essentia Health Hibbing Clinic

Address:
City: Hibbing
Zip: 55746
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 218-786-3308

Investigator:
Last name: Bret E. Friday
Email: Principal Investigator

Facility:
Name: Essentia Health Sandstone

Address:
City: Sandstone
Zip: 55072
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 218-786-3308
Email: CancerTrials@EssentiaHealth.org

Investigator:
Last name: Bret E. Friday
Email: Principal Investigator

Facility:
Name: Essentia Health Virginia Clinic

Address:
City: Virginia
Zip: 55792
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 218-786-3308
Email: CancerTrials@EssentiaHealth.org

Investigator:
Last name: Bret E. Friday
Email: Principal Investigator

Facility:
Name: Saint Francis Medical Center

Address:
City: Cape Girardeau
Zip: 63703
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 573-334-2230
Email: sfmc@sfmc.net

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Siteman Cancer Center at West County Hospital

Address:
City: Creve Coeur
Zip: 63141
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-600-3606
Email: info@siteman.wustl.edu

Investigator:
Last name: Premal H. Thaker
Email: Principal Investigator

Facility:
Name: Parkland Health Center - Farmington

Address:
City: Farmington
Zip: 63640
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 314-996-5569

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Washington University School of Medicine

Address:
City: Saint Louis
Zip: 63110
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-600-3606
Email: info@siteman.wustl.edu

Investigator:
Last name: Premal H. Thaker
Email: Principal Investigator

Facility:
Name: Siteman Cancer Center-South County

Address:
City: Saint Louis
Zip: 63129
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-600-3606
Email: info@siteman.wustl.edu

Investigator:
Last name: Premal H. Thaker
Email: Principal Investigator

Facility:
Name: Missouri Baptist Medical Center

Address:
City: Saint Louis
Zip: 63131
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 314-996-5569

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Siteman Cancer Center at Christian Hospital

Address:
City: Saint Louis
Zip: 63136
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-600-3606
Email: info@siteman.wustl.edu

Investigator:
Last name: Premal H. Thaker
Email: Principal Investigator

Facility:
Name: Siteman Cancer Center at Saint Peters Hospital

Address:
City: Saint Peters
Zip: 63376
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-600-3606
Email: info@siteman.wustl.edu

Investigator:
Last name: Premal H. Thaker
Email: Principal Investigator

Facility:
Name: Sainte Genevieve County Memorial Hospital

Address:
City: Sainte Genevieve
Zip: 63670
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 314-996-5569

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Missouri Baptist Sullivan Hospital

Address:
City: Sullivan
Zip: 63080
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 314-996-5569

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: BJC Outpatient Center at Sunset Hills

Address:
City: Sunset Hills
Zip: 63127
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 314-996-5569

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Community Hospital of Anaconda

Address:
City: Anaconda
Zip: 59711
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 406-969-6060
Email: mccinfo@mtcancer.org

Investigator:
Last name: John M. Schallenkamp
Email: Principal Investigator

Facility:
Name: Billings Clinic Cancer Center

Address:
City: Billings
Zip: 59101
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-996-2663
Email: research@billingsclinic.org

Investigator:
Last name: John M. Schallenkamp
Email: Principal Investigator

Facility:
Name: Bozeman Health Deaconess Hospital

Address:
City: Bozeman
Zip: 59715
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 406-969-6060
Email: mccinfo@mtcancer.org

Investigator:
Last name: John M. Schallenkamp
Email: Principal Investigator

Facility:
Name: Benefis Sletten Cancer Institute

Address:
City: Great Falls
Zip: 59405
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 406-969-6060
Email: mccinfo@mtcancer.org

Investigator:
Last name: John M. Schallenkamp
Email: Principal Investigator

Facility:
Name: Logan Health Medical Center

Address:
City: Kalispell
Zip: 59901
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 406-969-6060
Email: mccinfo@mtcancer.org

Investigator:
Last name: John M. Schallenkamp
Email: Principal Investigator

Facility:
Name: Community Medical Center

Address:
City: Missoula
Zip: 59804
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 406-969-6060
Email: mccinfo@mtcancer.org

Investigator:
Last name: John M. Schallenkamp
Email: Principal Investigator

Facility:
Name: OptumCare Cancer Care at Seven Hills

Address:
City: Henderson
Zip: 89052
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 702-384-0013
Email: research@sncrf.org

Investigator:
Last name: John A. Ellerton
Email: Principal Investigator

Facility:
Name: OptumCare Cancer Care at Charleston

Address:
City: Las Vegas
Zip: 89102
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 702-384-0013
Email: research@sncrf.org

Investigator:
Last name: John A. Ellerton
Email: Principal Investigator

Facility:
Name: OptumCare Cancer Care at Fort Apache

Address:
City: Las Vegas
Zip: 89148
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 702-384-0013
Email: research@sncrf.org

Investigator:
Last name: John A. Ellerton
Email: Principal Investigator

Facility:
Name: Rutgers Cancer Institute of New Jersey

Address:
City: New Brunswick
Zip: 08903
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 732-235-7356

Investigator:
Last name: Eugenia Girda
Email: Principal Investigator

Facility:
Name: University of New Mexico Cancer Center

Address:
City: Albuquerque
Zip: 87106
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 505-925-0348
Email: HSC-ClinicalTrialInfo@salud.unm.edu

Investigator:
Last name: Carolyn Y. Muller
Email: Principal Investigator

Facility:
Name: Roswell Park Cancer Institute

Address:
City: Buffalo
Zip: 14263
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-767-9355
Email: askroswell@roswellpark.org

Investigator:
Last name: Ellis G. Levine
Email: Principal Investigator

Facility:
Name: Mount Sinai Hospital

Address:
City: New York
Zip: 10029
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 212-824-7309
Email: CCTO@mssm.edu

Investigator:
Last name: Deborah B. Doroshow
Email: Principal Investigator

Facility:
Name: Duke University Medical Center

Address:
City: Durham
Zip: 27710
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 888-275-3853

Investigator:
Last name: Niharika B. Mettu
Email: Principal Investigator

Facility:
Name: Sanford Bismarck Medical Center

Address:
City: Bismarck
Zip: 58501
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 701-323-5760
Email: OncologyClinicalTrialsFargo@sanfordhealth.org

Investigator:
Last name: Daniel Almquist
Email: Principal Investigator

Facility:
Name: Sanford Broadway Medical Center

Address:
City: Fargo
Zip: 58122
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 701-323-5760
Email: OncologyClinicalTrialsFargo@sanfordhealth.org

Investigator:
Last name: Daniel Almquist
Email: Principal Investigator

Facility:
Name: Sanford Roger Maris Cancer Center

Address:
City: Fargo
Zip: 58122
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 701-234-6161
Email: OncologyClinicalTrialsFargo@sanfordhealth.org

Investigator:
Last name: Daniel Almquist
Email: Principal Investigator

Facility:
Name: Miami Valley Hospital South

Address:
City: Centerville
Zip: 45459
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 937-528-2900
Email: clinical.trials@daytonncorp.org

Investigator:
Last name: Tarek M. Sabagh
Email: Principal Investigator

Facility:
Name: Good Samaritan Hospital - Cincinnati

Address:
City: Cincinnati
Zip: 45220
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 720-874-1881
Email: ResearchInstituteInquiries@CommonSpirit.org

Investigator:
Last name: Shahzad Siddique
Email: Principal Investigator

Facility:
Name: Columbus Oncology and Hematology Associates Inc

Address:
City: Columbus
Zip: 43214
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 614-788-3860
Email: Jennifer.Sexton@ohiohealth.com

Investigator:
Last name: Aine E. Clements
Email: Principal Investigator

Facility:
Name: Riverside Methodist Hospital

Address:
City: Columbus
Zip: 43214
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 614-788-3860
Email: Jennifer.Sexton@ohiohealth.com

Investigator:
Last name: Aine E. Clements
Email: Principal Investigator

Facility:
Name: Grant Medical Center

Address:
City: Columbus
Zip: 43215
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 614-788-3860
Email: Jennifer.Sexton@ohiohealth.com

Investigator:
Last name: Aine E. Clements
Email: Principal Investigator

Facility:
Name: Doctors Hospital

Address:
City: Columbus
Zip: 43228
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 614-788-3860
Email: Jennifer.Sexton@ohiohealth.com

Investigator:
Last name: Aine E. Clements
Email: Principal Investigator

Facility:
Name: Miami Valley Hospital

Address:
City: Dayton
Zip: 45409
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 937-528-2900
Email: clinical.trials@daytonncorp.org

Investigator:
Last name: Tarek M. Sabagh
Email: Principal Investigator

Facility:
Name: Premier Blood and Cancer Center

Address:
City: Dayton
Zip: 45409
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 937-276-8320

Investigator:
Last name: Tarek M. Sabagh
Email: Principal Investigator

Facility:
Name: Dayton Physician LLC - Englewood

Address:
City: Dayton
Zip: 45415
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 937-528-2900
Email: clinical.trials@daytonncorp.org

Investigator:
Last name: Howard M. Gross
Email: Principal Investigator

Facility:
Name: Miami Valley Hospital North

Address:
City: Dayton
Zip: 45415
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 937-528-2900
Email: clinical.trials@daytonncorp.org

Investigator:
Last name: Tarek M. Sabagh
Email: Principal Investigator

Facility:
Name: Delaware Health Center-Grady Cancer Center

Address:
City: Delaware
Zip: 43015
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 614-788-3860
Email: Jennifer.Sexton@ohiohealth.com

Investigator:
Last name: Aine E. Clements
Email: Principal Investigator

Facility:
Name: Grady Memorial Hospital

Address:
City: Delaware
Zip: 43015
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 614-788-3860
Email: Jennifer.Sexton@ohiohealth.com

Investigator:
Last name: Aine E. Clements
Email: Principal Investigator

Facility:
Name: Columbus Oncology and Hematology Associates

Address:
City: Dublin
Zip: 43016
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 614-788-3860
Email: Jennifer.Sexton@ohiohealth.com

Investigator:
Last name: Aine E. Clements
Email: Principal Investigator

Facility:
Name: Dublin Methodist Hospital

Address:
City: Dublin
Zip: 43016
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 614-788-3860
Email: Jennifer.Sexton@ohiohealth.com

Investigator:
Last name: Aine E. Clements
Email: Principal Investigator

Facility:
Name: Atrium Medical Center-Middletown Regional Hospital

Address:
City: Franklin
Zip: 45005-1066
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 937-528-2900
Email: clinical.trials@daytonncorp.org

Investigator:
Last name: Tarek M. Sabagh
Email: Principal Investigator

Facility:
Name: Miami Valley Cancer Care and Infusion

Address:
City: Greenville
Zip: 45331
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 937-569-7515

Investigator:
Last name: Tarek M. Sabagh
Email: Principal Investigator

Facility:
Name: Kettering Medical Center

Address:
City: Kettering
Zip: 45429
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 937-528-2900
Email: clinical.trials@daytonncorp.org

Investigator:
Last name: Howard M. Gross
Email: Principal Investigator

Facility:
Name: OhioHealth Mansfield Hospital

Address:
City: Mansfield
Zip: 44903
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 614-788-3860
Email: Jennifer.Sexton@ohiohealth.com

Investigator:
Last name: Aine E. Clements
Email: Principal Investigator

Facility:
Name: OhioHealth Marion General Hospital

Address:
City: Marion
Zip: 43302
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 614-788-3860
Email: Jennifer.Sexton@ohiohealth.com

Investigator:
Last name: Aine E. Clements
Email: Principal Investigator

Facility:
Name: Upper Valley Medical Center

Address:
City: Troy
Zip: 45373
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 937-528-2900
Email: clinical.trials@daytonncorp.org

Investigator:
Last name: Tarek M. Sabagh
Email: Principal Investigator

Facility:
Name: University of Oklahoma Health Sciences Center

Address:
City: Oklahoma City
Zip: 73104
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 405-271-8777
Email: ou-clinical-trials@ouhsc.edu

Investigator:
Last name: Kathleen N. Moore
Email: Principal Investigator

Facility:
Name: Providence Newberg Medical Center

Address:
City: Newberg
Zip: 97132
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 503-215-2614
Email: CanRsrchStudies@providence.org

Investigator:
Last name: Alison K. Conlin
Email: Principal Investigator

Facility:
Name: Saint Alphonsus Cancer Care Center-Ontario

Address:
City: Ontario
Zip: 97914
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 406-969-6060
Email: mccinfo@mtcancer.org

Investigator:
Last name: John M. Schallenkamp
Email: Principal Investigator

Facility:
Name: Providence Willamette Falls Medical Center

Address:
City: Oregon City
Zip: 97045
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 503-215-2614
Email: CanRsrchStudies@providence.org

Investigator:
Last name: Alison K. Conlin
Email: Principal Investigator

Facility:
Name: Providence Portland Medical Center

Address:
City: Portland
Zip: 97213
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 503-215-2614
Email: CanRsrchStudies@providence.org

Investigator:
Last name: Alison K. Conlin
Email: Principal Investigator

Facility:
Name: Providence Saint Vincent Medical Center

Address:
City: Portland
Zip: 97225
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 503-215-2614
Email: CanRsrchStudies@providence.org

Investigator:
Last name: Alison K. Conlin
Email: Principal Investigator

Facility:
Name: UPMC Altoona

Address:
City: Altoona
Zip: 16601
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 773-702-9171
Email: protocols@AllianceNCTN.org

Investigator:
Last name: Sarah E. Taylor
Email: Principal Investigator

Facility:
Name: Bryn Mawr Hospital

Address:
City: Bryn Mawr
Zip: 19010
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 484-476-2649
Email: turzoe@mlhs.org

Investigator:
Last name: Paul B. Gilman
Email: Principal Investigator

Facility:
Name: UPMC Hillman Cancer Center Erie

Address:
City: Erie
Zip: 16505
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 412-389-5208
Email: haneydl@upmc.edu

Investigator:
Last name: Sarah E. Taylor
Email: Principal Investigator

Facility:
Name: UPMC Cancer Centers - Arnold Palmer Pavilion

Address:
City: Greensburg
Zip: 15601
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 724-838-1900

Investigator:
Last name: Sarah E. Taylor
Email: Principal Investigator

Facility:
Name: UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion

Address:
City: Mechanicsburg
Zip: 17050
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 412-389-5208
Email: haneydl@upmc.edu

Investigator:
Last name: Sarah E. Taylor
Email: Principal Investigator

Facility:
Name: Riddle Memorial Hospital

Address:
City: Media
Zip: 19063
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 484-476-2649
Email: turzoe@mlhs.org

Investigator:
Last name: Paul B. Gilman
Email: Principal Investigator

Facility:
Name: UPMC Hillman Cancer Center - Monroeville

Address:
City: Monroeville
Zip: 15146
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 412-389-5208
Email: haneydl@upmc.edu

Investigator:
Last name: Sarah E. Taylor
Email: Principal Investigator

Facility:
Name: Paoli Memorial Hospital

Address:
City: Paoli
Zip: 19301
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 484-476-2649
Email: turzoe@mlhs.org

Investigator:
Last name: Paul B. Gilman
Email: Principal Investigator

Facility:
Name: University of Pittsburgh Cancer Institute (UPCI)

Address:
City: Pittsburgh
Zip: 15232
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 412-647-8073

Investigator:
Last name: Sarah E. Taylor
Email: Principal Investigator

Facility:
Name: UPMC-Passavant Hospital

Address:
City: Pittsburgh
Zip: 15237
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 412-367-6454

Investigator:
Last name: Sarah E. Taylor
Email: Principal Investigator

Facility:
Name: Lankenau Medical Center

Address:
City: Wynnewood
Zip: 19096
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 484-476-2649
Email: turzoe@mlhs.org

Investigator:
Last name: Paul B. Gilman
Email: Principal Investigator

Facility:
Name: Women and Infants Hospital

Address:
City: Providence
Zip: 02905
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 401-274-1122

Investigator:
Last name: Matthew T. Oliver
Email: Principal Investigator

Facility:
Name: Prisma Health Cancer Institute - Butternut

Address:
City: Greenville
Zip: 29605
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 864-241-6251

Investigator:
Last name: Ki Y. Chung
Email: Principal Investigator

Facility:
Name: Sanford Cancer Center Oncology Clinic

Address:
City: Sioux Falls
Zip: 57104
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 605-312-3320
Email: OncologyClinicTrialsSF@sanfordhealth.org

Investigator:
Last name: Daniel Almquist
Email: Principal Investigator

Facility:
Name: Sanford USD Medical Center - Sioux Falls

Address:
City: Sioux Falls
Zip: 57117-5134
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 605-312-3320
Email: OncologyClinicalTrialsSF@SanfordHealth.org

Investigator:
Last name: Daniel Almquist
Email: Principal Investigator

Facility:
Name: Hendrick Medical Center

Address:
City: Abilene
Zip: 79601
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 325-670-6340

Investigator:
Last name: Mustapha A. Khalife
Email: Principal Investigator

Facility:
Name: Houston Methodist Hospital

Address:
City: Houston
Zip: 77030
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 713-790-2700

Investigator:
Last name: Monisha Singh
Email: Principal Investigator

Facility:
Name: M D Anderson Cancer Center

Address:
City: Houston
Zip: 77030
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 877-632-6789
Email: askmdanderson@mdanderson.org

Investigator:
Last name: Funda Meric-Bernstam
Email: Principal Investigator

Facility:
Name: Methodist Willowbrook Hospital

Address:
City: Houston
Zip: 77070
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 773-702-9171
Email: protocols@AllianceNCTN.org

Investigator:
Last name: Monisha Singh
Email: Principal Investigator

Facility:
Name: Houston Methodist West Hospital

Address:
City: Houston
Zip: 77094
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 832-522-2873

Investigator:
Last name: Monisha Singh
Email: Principal Investigator

Facility:
Name: Houston Methodist Saint John Hospital

Address:
City: Nassau Bay
Zip: 77058
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 773-702-9171
Email: protocols@AllianceNCTN.org

Investigator:
Last name: Monisha Singh
Email: Principal Investigator

Facility:
Name: Houston Methodist Sugar Land Hospital

Address:
City: Sugar Land
Zip: 77479
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 281-242-2873

Investigator:
Last name: Monisha Singh
Email: Principal Investigator

Facility:
Name: Houston Methodist The Woodlands Hospital

Address:
City: The Woodlands
Zip: 77385
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 713-790-2700
Email: hmthewoodlands@houstonmethodist.org

Investigator:
Last name: Monisha Singh
Email: Principal Investigator

Facility:
Name: Inova Schar Cancer Institute

Address:
City: Fairfax
Zip: 22031
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 703-720-5210
Email: Stephanie.VanBebber@inova.org

Investigator:
Last name: Timothy L. Cannon
Email: Principal Investigator

Facility:
Name: Inova Fairfax Hospital

Address:
City: Falls Church
Zip: 22042
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 703-208-6650
Email: Stephanie.VanBebber@inova.org

Investigator:
Last name: Timothy L. Cannon
Email: Principal Investigator

Facility:
Name: Swedish Cancer Institute-Edmonds

Address:
City: Edmonds
Zip: 98026
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 206-215-3086
Email: PCRC-NCORP@Swedish.org

Investigator:
Last name: Alison K. Conlin
Email: Principal Investigator

Facility:
Name: Swedish Cancer Institute-Issaquah

Address:
City: Issaquah
Zip: 98029
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 206-215-3086
Email: PCRC-NCORP@Swedish.org

Investigator:
Last name: Alison K. Conlin
Email: Principal Investigator

Facility:
Name: Swedish Medical Center-First Hill

Address:
City: Seattle
Zip: 98122
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 206-215-3086
Email: PCRC-NCORP@Swedish.org

Investigator:
Last name: Alison K. Conlin
Email: Principal Investigator

Facility:
Name: West Virginia University Healthcare

Address:
City: Morgantown
Zip: 26506
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 304-293-7374
Email: cancertrialsinfo@hsc.wvu.edu

Investigator:
Last name: Nour Daboul
Email: Principal Investigator

Facility:
Name: ThedaCare Regional Cancer Center

Address:
City: Appleton
Zip: 54911
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 920-364-3604
Email: ResearchDept@thedacare.org

Investigator:
Last name: Matthias Weiss
Email: Principal Investigator

Facility:
Name: Duluth Clinic Ashland

Address:
City: Ashland
Zip: 54806
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 218-786-3308
Email: CancerTrials@EssentiaHealth.org

Investigator:
Last name: Bret E. Friday
Email: Principal Investigator

Facility:
Name: Aurora Cancer Care-Southern Lakes VLCC

Address:
City: Burlington
Zip: 53105
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 414-302-2304
Email: ncorp@aurora.org

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: Aurora Saint Luke's South Shore

Address:
City: Cudahy
Zip: 53110
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 414-302-2304
Email: ncorp@aurora.org

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: Marshfield Medical Center-EC Cancer Center

Address:
City: Eau Claire
Zip: 54701
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-782-8581
Email: oncology.clinical.trials@marshfieldresearch.org

Investigator:
Last name: Adedayo A. Onitilo
Email: Principal Investigator

Facility:
Name: Aurora Health Care Germantown Health Center

Address:
City: Germantown
Zip: 53022
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 414-302-2304
Email: ncorp@aurora.org

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: Aurora Cancer Care-Grafton

Address:
City: Grafton
Zip: 53024
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 414-302-2304
Email: ncorp@aurora.org

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: Saint Vincent Hospital Cancer Center Green Bay

Address:
City: Green Bay
Zip: 54301
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 920-433-8889
Email: ewd_research_admin@hshs.org

Investigator:
Last name: Anthony J. Jaslowski
Email: Principal Investigator

Facility:
Name: Saint Vincent Hospital Cancer Center at Saint Mary's

Address:
City: Green Bay
Zip: 54303
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 920-433-8889
Email: ewd_research_admin@hshs.org

Investigator:
Last name: Anthony J. Jaslowski
Email: Principal Investigator

Facility:
Name: Aurora BayCare Medical Center

Address:
City: Green Bay
Zip: 54311
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 414-302-2304
Email: ncorp@aurora.org

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: Mercyhealth Hospital and Cancer Center - Janesville

Address:
City: Janesville
Zip: 53548
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 608-756-6871
Email: oncologyclinicaltrials@mhemail.org

Investigator:
Last name: Emily G. Robinson
Email: Principal Investigator

Facility:
Name: Aurora Cancer Care-Kenosha South

Address:
City: Kenosha
Zip: 53142
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 414-302-2304
Email: ncorp@aurora.org

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: Gundersen Lutheran Medical Center

Address:
City: La Crosse
Zip: 54601
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 608-775-2385
Email: cancerctr@gundersenhealth.org

Investigator:
Last name: Michael O. Ojelabi
Email: Principal Investigator

Facility:
Name: University of Wisconsin Carbone Cancer Center - Eastpark Medical Center

Address:
City: Madison
Zip: 53718
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-622-8922
Email: clinicaltrials@cancer.wisc.edu

Investigator:
Last name: Dustin A. Deming
Email: Principal Investigator

Facility:
Name: University of Wisconsin Carbone Cancer Center - University Hospital

Address:
City: Madison
Zip: 53792
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-622-8922
Email: clinicaltrials@cancer.wisc.edu

Investigator:
Last name: Dustin A. Deming
Email: Principal Investigator

Facility:
Name: Aurora Bay Area Medical Group-Marinette

Address:
City: Marinette
Zip: 54143
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 414-302-2304
Email: ncorp@aurora.org

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: Aurora Cancer Care-Milwaukee

Address:
City: Milwaukee
Zip: 53209
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 414-302-2304
Email: ncorp@aurora.org

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: Aurora Saint Luke's Medical Center

Address:
City: Milwaukee
Zip: 53215
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 414-302-2304
Email: ncorp@aurora.org

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: Aurora Sinai Medical Center

Address:
City: Milwaukee
Zip: 53233
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 414-302-2304
Email: ncorp@aurora.org

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: Saint Vincent Hospital Cancer Center at Oconto Falls

Address:
City: Oconto Falls
Zip: 54154
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 920-433-8889
Email: ewd_research_admin@hshs.org

Investigator:
Last name: Anthony J. Jaslowski
Email: Principal Investigator

Facility:
Name: Vince Lombardi Cancer Clinic - Oshkosh

Address:
City: Oshkosh
Zip: 54904
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 414-302-2304
Email: ncorp@aurora.org

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: Aurora Cancer Care-Racine

Address:
City: Racine
Zip: 53406
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 414-302-2304
Email: ncorp@aurora.org

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: Vince Lombardi Cancer Clinic-Sheboygan

Address:
City: Sheboygan
Zip: 53081
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 414-302-2304
Email: ncorp@aurora.org

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: Marshfield Medical Center-River Region at Stevens Point

Address:
City: Stevens Point
Zip: 54482
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-782-8581
Email: oncology.clinical.trials@marshfieldresearch.org

Investigator:
Last name: Adedayo A. Onitilo
Email: Principal Investigator

Facility:
Name: Saint Vincent Hospital Cancer Center at Sturgeon Bay

Address:
City: Sturgeon Bay
Zip: 54235-1495
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 920-433-8889
Email: ewd_research_admin@hshs.org

Investigator:
Last name: Anthony J. Jaslowski
Email: Principal Investigator

Facility:
Name: Aurora Medical Center in Summit

Address:
City: Summit
Zip: 53066
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 414-302-2304
Email: ncorp@aurora.org

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: Vince Lombardi Cancer Clinic-Two Rivers

Address:
City: Two Rivers
Zip: 54241
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 414-302-2304
Email: ncorp@aurora.org

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: Aurora Cancer Care-Milwaukee West

Address:
City: Wauwatosa
Zip: 53226
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 414-302-2304
Email: ncorp@aurora.org

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: Aurora West Allis Medical Center

Address:
City: West Allis
Zip: 53227
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 414-302-2304
Email: ncorp@aurora.org

Investigator:
Last name: Thomas J. Saphner
Email: Principal Investigator

Facility:
Name: Marshfield Medical Center - Weston

Address:
City: Weston
Zip: 54476
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-782-8581
Email: oncology.clinical.trials@marshfieldresearch.org

Investigator:
Last name: Adedayo A. Onitilo
Email: Principal Investigator

Facility:
Name: Centro Comprensivo de Cancer de UPR

Address:
City: San Juan
Zip: 00927
Country: Puerto Rico

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 888-823-5923
Email: ctsucontact@westat.com

Investigator:
Last name: Luis J. Santos Reyes
Email: Principal Investigator

Start date: December 13, 2023

Completion date: August 26, 2026

Lead sponsor:
Agency: National Cancer Institute (NCI)
Agency class: NIH

Source: National Cancer Institute (NCI)

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05554367

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

To hear about similar clinical trials, please enter your email below

Login to your account